Exploring High Growth Tech Stocks In South Korea October 2024

The South Korean stock market recently broke a three-day losing streak, with the KOSPI index closing modestly higher, though it remains susceptible to renewed selling pressures amid a generally negative global forecast. In this fluctuating environment, identifying high growth tech stocks requires careful consideration of market resilience and the potential for technological innovation to drive future performance.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
IMLtd	21.80%	111.43%	★★★★★★
Seojin SystemLtd	33.39%	49.13%	★★★★★★
Bioneer	23.53%	97.58%	★★★★★★
NEXON Games	29.64%	66.98%	★★★★★★
FLITTO	32.60%	106.82%	★★★★★★
ALTEOGEN	64.22%	99.46%	★★★★★★
Devsisters	29.08%	63.02%	★★★★★★
Park Systems	23.21%	34.63%	★★★★★★
AmosenseLtd	24.04%	71.97%	★★★★★★
UTI	114.97%	134.60%	★★★★★★

Click here to see the full list of 47 stocks from our KRX High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company that specializes in developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩21.12 trillion.

Operations: The company focuses on generating revenue primarily from its biotechnology segment, which reported ₩90.79 billion. It is involved in the development of long-acting biobetters and antibody-related products.

ALTEOGEN is navigating the competitive landscape of South Korea's tech sector with an impressive forecasted revenue growth rate of 64.2% annually, significantly outpacing the national market average of 10.2%. Despite current unprofitability, the firm is poised for a turnaround with earnings expected to surge by 99.5% per year. This growth trajectory is underpinned by substantial R&D investments, which are integral to ALTEOGEN's strategy for capturing market share and driving innovation in biotechnology—a field where research intensity often correlates directly with long-term success. As it moves towards profitability within three years, its strategic focus on developing proprietary technologies could set new industry standards, although shareholder dilution over the past year remains a concern.

• Dive into the specifics of ALTEOGEN here with our thorough health report.

• Gain insights into ALTEOGEN's past trends and performance with our Past report.

ISU Petasys (KOSE:A007660)

Simply Wall St Growth Rating: ★★★★★☆

Overview: ISU Petasys Co., Ltd. is a global manufacturer and seller of printed circuit boards (PCBs) with a market capitalization of ₩2.75 billion.

Operations: ISU Petasys generates revenue primarily through the manufacture and sale of printed circuit boards, amounting to ₩743.88 billion. The company's market capitalization stands at ₩2.75 trillion, positioning it as a significant player in the global PCB industry.

ISU Petasys, amid South Korea's bustling tech scene, is navigating a challenging environment marked by a volatile share price but shows promise with forecasted revenue growth of 18.6% annually. This growth is notably higher than the national market average of 10.2%. Despite a downturn in earnings last year by 34.1%, future projections are optimistic with an anticipated profit surge of 44.4% per year, outpacing the broader Korean market's expectation of 29.3%. Central to ISU Petasys' strategy are its R&D investments which have been pivotal in maintaining competitive edge and fostering innovation within the electronic sector—a critical factor given the direct correlation between research intensity and long-term success in tech industries.

• Click here and access our complete health analysis report to understand the dynamics of ISU Petasys.

• Examine ISU Petasys' past performance report to understand how it has performed in the past.

HYBE (KOSE:A352820)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: HYBE Co., Ltd. operates in the music production, publishing, and artist development and management sectors with a market capitalization of ₩8.09 trillion.

Operations: HYBE Co., Ltd. generates revenue primarily from its Label and Solution segments, contributing ₩1.28 trillion and ₩1.24 trillion respectively, while the Platform segment adds ₩361.12 billion to its income stream. The company focuses on music production, publishing, and artist management as core components of its business model.

HYBE, amidst South Korea's dynamic tech landscape, is carving a niche with an impressive 13.7% annual revenue growth, outpacing the national market average. This growth trajectory is bolstered by strategic R&D investments that have surged to 42.6% of total expenditures, underpinning innovation and competitive positioning in the entertainment technology sector. Recently, HYBE reinforced its market strategy through a share repurchase program totaling KRW 26.09 billion, reflecting confidence in its financial health and future prospects. This move aligns with its robust earnings forecast which expects a significant leap by 42.61% annually, showcasing potential for sustained profitability and industry leadership.

• Click here to discover the nuances of HYBE with our detailed analytical health report.

• Learn about HYBE's historical performance.

Turning Ideas Into Actions

• Unlock more gems! Our KRX High Growth Tech and AI Stocks screener has unearthed 44 more companies for you to explore.Click here to unveil our expertly curated list of 47 KRX High Growth Tech and AI Stocks.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com